The results of innovative products for the treatment of COVID-19, cancer, neurodegenerative diseases, as well as for food production will be presented at the BioHabana 2022 Congress from April 25 to 29.
The event, convened by the BioCubaFarma Business Group, will become a space for exchange between scientists from Cuba and the world about the main challenges of the biotechnology and pharmaceutical sector, Eduardo Martínez Díaz, president of that entity, said today at a press conference. and the BioHabana 2022 Organizing Committee.
He mentioned that among the products that will be discussed are those linked to cancer such as the CIMAvax-EGF vaccine, Nimotuzumab and HeberFERON, in addition to NeuroEpo for conditions such as Alzheimer’s and its evaluation in Parkinson’s.
Likewise, the meeting will address the effectiveness results of Cuban anti-COVID-19 vaccines, the new generations of these from the genetic variants of SARS-CoV-2, as is the case of omicron, and therapeutic products. that were redirected for virus treatment.
BioHabana 2022’s main themes are the COVID-19 pandemic, medical technology, industry 4.0, chronic inflammation and ageing, brain diseases and cancer immunotherapy.
In turn, during the event, bioprocesses, their developability and design space, and innovation in new business models for high-tech sectors will be discussed.
Agricultural biotechnology will be another of the topics to be discussed through its link with food production in an environmentally friendly way and BioCubaFarma’s portfolio of veterinary vaccines will be presented.
Rolando Pérez Rodríguez, executive secretary of the Scientific Committee of the event and director of Science and Innovation of BioCubaFarma, affirmed that the Congress intends to cover the entire spectrum of innovation that the biopharmaceutical industry works on.
He specified that it will include virtual and face-to-face spaces for conducting pre-congress courses, symposiums with conferences by renowned scientists and workshops where papers will be presented.
Likewise, the launch of BioCubaFarma’s business and innovation folders will be held, in addition to an exhibition fair.
So far, more than 100 researchers and businessmen from 15 countries have expressed their interest in participating and academics from several US universities have been invited.
